Biocartis announced that bioMérieux and Biocartis have signed an agreement to end their alliance for the development and commercialization of the integrated molecular biology system, Idylla(TM) (previously Apollo), in the field of microbiology molecular diagnostics. bioMérieux will return all rights on the Idylla(TM) platform to Biocartis.
